Repositioning Immunotherapy in VetArans With Lung Cancer

Summary

This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.

Eligibility

Inclusion Criteria:

* Patient must have a performance status of 0-1 (ECOG Performance Scale)
* Patient must be a candidate for concurrent chemoradiation
* Unresectable Stage III NSCLC as assessed by investigator or multidisciplinary tumor board assessment
* PD-L1 tumor expression greater than or equal to 1%
* Presence of measurable disease according to RECIST v1.1
* Adequate organ function
* Available tissue (archival FFPE preferred) with adequate tumor content ( 20% tumor cellularity)

Exclusion Criteria:

* Active autoimmune disease that has requires immunosuppressive therapy in the previous year
* Uncontrolled primary or acquired immunodeficiency (including HIV)
* Baseline corticosteroid usage (\>10 mg prednisone or equivalent daily) aside from supportive medication use
* Tumor with known EGFR, ALK, ROS1, MET or RET mutations/fusions
* Presence of significant comorbidities precluding participation in a clinical study as determined by investigator
* Prior thoracic radiotherapy or prior systemic treatment for stage IIIB/IV NSCLC
* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with informed consent through 180 days after the last dose of trial treatment
* Has a known history of active TB (Bacillus Tuberculosis)
* Has known active Hepatitis B or Hepatitis C
* Has received a live vaccine within 30 days of enrollment
* Known diagnosis of Interstitial Lung Disease
* Inability to provide informed consent

Conditions3

Interventions1

Locations7 sites

Find trials near these locations

Related trials

• A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study — LaNova Medicines Zhejiang Co., Ltd.
• A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) — Daniel Morgenstern
• A Study of BND-35 in Participants With Advanced Solid Tumors — Biond Biologics
• A Study of TRK-950 in Patients With Advanced Solid Tumors — Toray Industries, Inc
• A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma — University Health Network, Toronto
• A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors — Suzhou Transcenta Therapeutics Co., Ltd.
• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma — Gustave Roussy, Cancer Campus, Grand Paris
• Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients — Sheba Medical Center

Browse More Trials